Compare MVBF & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVBF | INBX |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.6M | 1.5B |
| IPO Year | 2004 | 2024 |
| Metric | MVBF | INBX |
|---|---|---|
| Price | $30.70 | $108.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $29.50 | ★ $150.00 |
| AVG Volume (30 Days) | 46.9K | ★ 322.5K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 34.64 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $3,400,000.00 | $1,300,000.00 |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | $23.36 | ★ N/A |
| Revenue Growth | 51.92 | ★ 550.00 |
| 52 Week Low | $23.99 | $26.20 |
| 52 Week High | $31.99 | $155.29 |
| Indicator | MVBF | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 49.61 |
| Support Level | $29.34 | $96.60 |
| Resistance Level | $31.70 | $153.14 |
| Average True Range (ATR) | 0.78 | 8.01 |
| MACD | -0.04 | -2.50 |
| Stochastic Oscillator | 45.99 | 38.52 |
MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.